Moreover, we identified EGFR L861Q and MET amplification as two unique actionable alterations in pericardial effusion, suggesting that NGS sequencing on pericardial effusion could lead to identification of advanced NSCLC patients who are qualified for TKI based therapy. Here, EGFR is linked to non-small cell lung carcinoma.